Compare ADPT & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | CCS |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2019 | 2014 |
| Metric | ADPT | CCS |
|---|---|---|
| Price | $14.81 | $56.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $17.78 | ★ $70.50 |
| AVG Volume (30 Days) | ★ 2.2M | 213.6K |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 4.86 |
| Revenue | $276,976,000.00 | ★ $4,117,816,000.00 |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | $10.84 |
| P/E Ratio | ★ N/A | $11.73 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $6.71 | $50.42 |
| 52 Week High | $20.76 | $76.00 |
| Indicator | ADPT | CCS |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 37.90 |
| Support Level | $12.24 | $56.43 |
| Resistance Level | $17.52 | $58.50 |
| Average True Range (ATR) | 0.72 | 1.78 |
| MACD | 0.21 | 0.32 |
| Stochastic Oscillator | 97.21 | 53.48 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.